Pre-clinical validation of a pan-cancer CAR-T cell immunotherapy targeting nfP2X7
V. Bandara, J. Foeng, et al.
Explore these studies to deepen your understanding
Adjacent work that informs or extends this paper's methodology and findings.
A type I interferon footprint in pre-operative biopsies is an independent biomarker that in combination with CD8+ T cell quantification can improve the prediction of response to neoadjuvant treatment of rectal adenocarcinoma
A. Rezapour, D. Rydbeck, et al.
Efficacy and safety of nanoparticle albumin-bound paclitaxel monotherapy after immune checkpoint inhibitor administration for advanced non-small cell lung cancer: A multicenter Phase 2 clinical trial
T. Sonoda, Y. Umeda, et al.
Locoregional delivery of IL-13Rx2-targeting CAR-T cells in recurrent high-grade glioma: a phase 1 trial
C. E. Brown, J. C. Hibbard, et al.
PSCA-CAR T cell therapy in metastatic castration-resistant prostate cancer: a phase 1 trial
T. B. Dorff, M. S. Blanchard, et al.
